Press Releases

PRESS RELEASE 31 Oct 2018 at 11:00

Boehringer Ingelheim Announces Growth in the Bay Area

PRESS RELEASE 29 Aug 2017 at 09:13

Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for Cyltezo^TM (adalimumab-adbm), a biosimilar to Humira^{^®}, for the treatment of multiple chronic inflammatory diseases

Read more on

Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for Cyltezo^TM (adalimumab-adbm), a biosimilar to Humira^{^®}, for the treatment of multiple chronic inflammatory diseases

PRESS RELEASE 27 Jul 2017 at 09:10

Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and U.S.-formulated Humira^{^®}

Read more on

Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and U.S.-formulated Humira^{^®}

PRESS RELEASE 21 Jul 2017 at 15:06

Boehringer Ingelheim Breaks Ground on $217 Million Expansion of Fremont, California Manufacturing Facility

Boehringer Ingelheim Statement

Boehringer Ingelheim Statement: Favorable Ruling on Humira^{^®} Patent Challenge from U.S. Patent and Trademark Office

Read more on

Boehringer Ingelheim Statement: Favorable Ruling on Humira^{^®} Patent Challenge from U.S. Patent and Trademark Office

PRESS RELEASE 18 Jan 2017 at 09:00

Boehringer Ingelheim biosimilar candidate to Humira^{^®} accepted for EMA and FDA regulatory review

Read more on

Boehringer Ingelheim biosimilar candidate to Humira^{^®} accepted for EMA and FDA regulatory review

Search form